CSF levels of GAP‐43 were notably higher in AD patients compared to controls and other NDs and showed a positive connection with the extent of deposition of NFT and Aβ plaques in the hippocampus, amygdala, and cortex. Here, GAP43 is linked to Alzheimer disease.